[go: up one dir, main page]

NO20082862L - Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav - Google Patents

Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav

Info

Publication number
NO20082862L
NO20082862L NO20082862A NO20082862A NO20082862L NO 20082862 L NO20082862 L NO 20082862L NO 20082862 A NO20082862 A NO 20082862A NO 20082862 A NO20082862 A NO 20082862A NO 20082862 L NO20082862 L NO 20082862L
Authority
NO
Norway
Prior art keywords
reduced cytotoxicity
derivatives
novel alkylphospholipid
alkylphospholipid derivatives
novel
Prior art date
Application number
NO20082862A
Other languages
English (en)
Inventor
Juergen Engel
Daniel Perrissoud
Mathias Pietras
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05027823A external-priority patent/EP1800684A1/en
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of NO20082862L publication Critical patent/NO20082862L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer nye alkylfosfolipidderivater med redusert cytotoksisitet som er nyttige for å behandle ulike sykdommer og/eller patofysiologiske tilstander i pattedyr, fortrinnsvis mennesker, som er forårsaket ved mikroorganismer, spesielt bakterier, sopp, protozoer og/eller virus. Slike alkylfosfolipider kan bli benyttet som enkle medikamenter eller i forløpet av kombinasjonsterapier og kan også bli benyttet for behandlingen av tumorer.
NO20082862A 2005-12-19 2008-06-23 Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav NO20082862L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75143805P 2005-12-19 2005-12-19
EP05027823A EP1800684A1 (en) 2005-12-20 2005-12-20 Novel alkyl phospholipid derivatives and uses thereof
PCT/EP2006/069873 WO2007071658A2 (en) 2005-12-19 2006-12-19 Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof

Publications (1)

Publication Number Publication Date
NO20082862L true NO20082862L (no) 2008-08-27

Family

ID=37942171

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082862A NO20082862L (no) 2005-12-19 2008-06-23 Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav

Country Status (12)

Country Link
EP (1) EP1962862B1 (no)
JP (1) JP5232009B2 (no)
KR (1) KR101378005B1 (no)
AR (1) AR058397A1 (no)
AU (1) AU2006328479B2 (no)
CA (1) CA2632449A1 (no)
IL (1) IL191695A (no)
NO (1) NO20082862L (no)
PL (1) PL1962862T3 (no)
RU (1) RU2469727C2 (no)
UY (1) UY30042A1 (no)
WO (1) WO2007071658A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600429A (zh) * 2006-12-08 2009-12-09 哈多技术有限公司 治疗和预防传染性疾病的胆固醇胺
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
AT505515B1 (de) * 2007-08-02 2009-04-15 Orphanidis Pharma Res Verwendung von miltefosin zur herstellung eines medikaments zur behandlung der cryptosporidiose beim menschen
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
US20130345177A1 (en) * 2011-03-04 2013-12-26 Dafra Pharma Research & Development Bvba Oleyl Phosphocholine for the Treatment of Mycosis
CN102584926B (zh) * 2012-01-12 2014-10-15 浙江大学 利用基于胆固醇和磷酸胆碱两亲小分子制备超分子水凝胶的方法
RU2487708C1 (ru) * 2012-03-12 2013-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) Способ лечения парвовирусной инфекции в19 у детей раннего возраста
US10562849B2 (en) * 2016-05-16 2020-02-18 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
MX2020003286A (es) * 2017-09-21 2020-10-01 Scripps Research Inst Nuevas terapias para tratar y prevenir la rinosinusitis crónica.
ES2739773B2 (es) * 2018-08-02 2020-11-17 Univ Alicante Compuestos zwitterionicos de acidos 2-fosfocolina carboxilicos y su uso como agentes citotoxicos
AU2020395150A1 (en) * 2019-12-02 2022-06-23 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
IE59778B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
ES2058260T3 (es) 1987-03-24 1994-11-01 Nippon Chemiphar Co Un proceso para la preparacion de un derivado del glicerol.
DE3942933A1 (de) * 1989-12-23 1991-06-27 Boehringer Mannheim Gmbh Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
ES2086026T3 (es) 1991-07-04 1996-06-16 Asta Medica Ag Farmaco con efecto antineoplasico que contiene como sustancia activa (2-(n-metil-piperidino)-etil)-fosfato de octadecilo y procedimiento para su preparacion.
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
FR2683915A1 (fr) * 1991-11-18 1993-05-21 Philips Electronique Lab Appareil d'examen de milieux par echographie ultrasonore.
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
DE4233044A1 (de) 1992-10-01 1994-04-07 Asta Medica Ag Phospholipidderivate, die höhere Elemente der V. Hauptgruppe enthalten
US5958906A (en) 1992-10-01 1999-09-28 Asta-Medica Aktiengesellschaft Phospholipid derivatives containing higher elements of the fifth main group
DE19650778C2 (de) 1996-12-06 2001-01-04 Asta Medica Ag Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie
JP3367892B2 (ja) * 1997-05-22 2003-01-20 株式会社ヨシツカ精機 多段粉末成形プレス
DE19835611A1 (de) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
ATE226843T1 (de) * 1998-12-04 2002-11-15 Max Delbrueck Centrum Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
US6521879B1 (en) 2001-04-20 2003-02-18 Rockwell Collins, Inc. Method and system for controlling an LED backlight in flat panel displays wherein illumination monitoring is done outside the viewing area
DE10148067A1 (de) * 2001-09-28 2003-04-17 Max Planck Gesellschaft Hitzesterilisierbare Alkylphosphocholin-Liposome
JP2005515224A (ja) * 2002-01-14 2005-05-26 ダウ グローバル テクノロジーズ インコーポレイティド テンプレート乳剤からの薬剤ナノ粒子
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
US7410955B2 (en) * 2002-03-25 2008-08-12 Biosynergen, Inc. Therapeutic use of agonist ligands specific to G2A receptor
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
CA2503058A1 (en) * 2002-10-30 2004-05-21 Theodora Calogeropoulou Antiprotozoal ring-substituted phospholipids
WO2006081452A2 (en) * 2005-01-28 2006-08-03 Robert Birch Co-administration of perifosine with chemotherapeutics
WO2006122716A1 (en) * 2005-05-18 2006-11-23 Heidelberg Pharma Gmbh Use of ether-linked lysophosphatidylcholines and alkylphosphocholines for the treatment of papilloma virus induced warts and sarcoids

Also Published As

Publication number Publication date
AU2006328479B2 (en) 2012-03-08
RU2469727C2 (ru) 2012-12-20
AR058397A1 (es) 2008-01-30
JP5232009B2 (ja) 2013-07-10
HK1124775A1 (en) 2009-07-24
RU2008129597A (ru) 2010-01-27
WO2007071658A3 (en) 2007-10-04
IL191695A (en) 2013-12-31
EP1962862A2 (en) 2008-09-03
UY30042A1 (es) 2007-07-31
KR20080081326A (ko) 2008-09-09
AU2006328479A1 (en) 2007-06-28
PL1962862T3 (pl) 2014-01-31
JP2009519999A (ja) 2009-05-21
KR101378005B1 (ko) 2014-03-27
CA2632449A1 (en) 2007-06-28
EP1962862B1 (en) 2013-09-04
WO2007071658A2 (en) 2007-06-28
IL191695A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
NO20082862L (no) Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav
ATE481134T1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20084749L (no) Organiske forbindelser og deres anvendelser
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
EP2402443A3 (en) Therapeutic uses of inhibitors of rtp801
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
IS8591A (is) Ný notkun
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2008082692A3 (en) Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
UA99434C2 (ru) Применение производных алкилфосфолипидов со сниженной цитотоксичностью
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
WO2010052575A3 (en) Ngna compositions and methods of use
HK1256029A1 (zh) 新型虎杖提取物及它们作为光动力灭活剂的用途

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application